STRATEC Biomedical AG 

16.12.2013 15:40

Dissemination of a Voting Rights Announcement, transmitted by DGAP - a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---

Allianz SE, Munich, Germany, notified us on December 12, 2013 pursuant to section 21 (1) of the German Securities Trading Act (WpHG) as follows:
'We hereby give notice pursuant to section 21 (1) of the German Securities Trading Act (WpHG) that our voting rights in STRATEC Biomedical AG, Gewerbestr. 37, 75217 Birkenfeld, Germany, exceeded the threshold of 5% on December 10, 2013 and amounted to 5.11% of all voting rights in the company, corresponding to 601,001 of the total 11,770,245 voting rights.
These voting rights are attributed to us pursuant to section 22 (1) sentence 1 number 1 of the German Securities Trading Act (WpHG) and pursuant to section 22 (1) sentence 1 number 6 in conjunction with sentence 2 of the German Securities Trading Act (WpHG).

The 600,000 voting rights attributable to us pursuant to section 22 (1) sentence 1 number 1 of the German Securities Trading Act (WpHG) are held via the following subsidiaries controlled by us whose share of voting rights in STRATEC Biomedical AG amounted in each case to 3% or more: Allianz Europe B.V., Allianz Holding France SAS, Allianz France S.A. and Allianz I.A.R.D. S.A.

These 600,000 voting rights were also attributable to us pursuant to section 22 (1) sentence 1 number 6 in conjunction with sentence 2 of the German Securities Trading Act (WpHG) via a shareholder whose share of voting rights amounted to 3% or more: Allianz I.A.R.D. S.A.'


Moreover, Allianz SE, Munich, Germany, notified us on December 12, 2013 pursuant to section 25 (1) of the German Securities Trading Act (WpHG) as follows:

'We also hereby give notice pursuant to section 25 (1) of the German Securities Trading Act (WpHG) that our share of voting rights in STRATEC Biomedical AG, Gewerbestr. 37, 75217 Birkenfeld, Germany, exceeded the threshold of 5% on December 10, 2013 and amounted to 5.18% of all voting rights in the company, corresponding to 610,001 of the total 11,770,245 voting rights. Due to (financial/other) instruments, the share of voting rights pursuant to section 25 of the German Securities Trading Act (WpHG) amounted to 0.08%, corresponding to 9,000 of the total 11,770,245 voting rights. Of these, 0.08% were held indirectly, corresponding to 9,000 of the total 11,770,245 voting rights. The share of voting rights pursuant to sections 21 and 22 of the German Securities Trading Act (WpHG) amounted to 5.11%, corresponding to 601,001 of the total 11,770,245 voting rights.
The chain of controlled companies, which held voting rights pursuant to section 25 (1) of the German Securities Trading Act (WpHG), was as follows: Allianz Deutschland AG and Allianz Private Krankenversicherungs-AG.
The financial/other instruments pursuant to section 25 of the German Securities Trading Act (WpHG) were return claims arising from securities lending with indefinite maturities.'



Moreover, Allianz SE, Munich, Germany, notified us on December 12, 2013 pursuant to section 21 (1) of the German Securities Trading Act (WpHG) in conjunction with section 24 (1) of the German Securities Trading Act (WpHG) as follows:

'1. The share of voting rights held by Allianz Europe B.V., Amsterdam, Netherlands, in STRATEC Biomedical AG, Gewerbestr. 37, 75217 Birkenfeld, Germany, exceeded the threshold of 5% on December 10, 2013 and amounted to 5.10% of all voting rights in the company, corresponding to 600,000 of the total 11,770,245 voting rights. These voting rights are attributed to Allianz Europe B.V. pursuant to section 22 (1) sentence 1 number 1 of the German Securities Trading Act (WpHG).

The voting rights attributed to Allianz Europe B.V. were held via the following companies controlled by Allianz Europe B.V. whose share of the voting rights in STRATEC Biomedical AG amounted to 3% or more in each case: Allianz Holding France SAS, Allianz France S.A., and Allianz I.A.R.D. S.A.

2. The share of voting rights held by Allianz Holding France SAS, Paris, France, in STRATEC Biomedical AG, Gewerbestr. 37, 75217 Birkenfeld, Germany, exceeded the threshold of 5% on December 10, 2013 and amounted to 5.10% of all voting rights in the company, corresponding to 600,000 of the total 11,770,245 voting rights. These voting rights are attributed to Allianz Holding France SAS pursuant to section 22 (1) sentence 1 number 1 of the German Securities Trading Act (WpHG).

The voting rights attributed to Allianz Holding France SAS were held via the following companies controlled by Allianz Holding France SAS whose share of the voting rights in STRATEC Biomedical AG amounted to 3% or more in each case: Allianz France S.A. and Allianz I.A.R.D. S.A.

3. The share of voting rights held by Allianz France S.A., Paris, France, in STRATEC Biomedical AG, Gewerbestr. 37, 75217 Birkenfeld, Germany, exceeded the threshold of 5% on December 10, 2013 and amounted to 5.10% of all voting rights in the company, corresponding to 600,000 of the total 11,770,245 voting rights. These voting rights are attributed to Allianz France S.A. pursuant to section 22 (1) sentence 1 number 1 of the German Securities Trading Act (WpHG).

The voting rights attributed to Allianz France S.A. were held via the following company controlled by Allianz France S.A. whose share of the voting rights in STRATEC Biomedical AG amounted to 3% or more: Allianz I.A.R.D. S.A.


4. The share of voting rights held by Allianz I.A.R.D. S.A., Paris, France, in STRATEC Biomedical AG, Gewerbestr. 37, 75217 Birkenfeld, Germany, exceeded the threshold of 5% on December 10, 2013 and amounted to 5.10% of all voting rights in the company, corresponding to 600,000 of the total 11,770,245 voting rights.


5. The share of voting rights held by Allianz Asset Management AG, Munich, Germany, in STRATEC Biomedical AG, Gewerbestr. 37, 75217 Birkenfeld, Germany, exceeded the threshold of 5% on December 10, 2013 and amounted to 5.11% of all voting rights in the company, corresponding to 601,001 of the total 11,770,245 voting rights. These voting rights are attributed pursuant to section 22 (1) sentence 1 number 6 in conjunction with sentence 2 of the German Securities Trading Act (WpHG).

Of these, 600,000 voting rights were also attributable to us pursuant to section 22 (1) sentence 1 number 6 in conjunction with sentence 2 of the German Securities Trading Act (WpHG) via a shareholder whose share of voting rights amounted to 3% or more: Allianz I.A.R.D. S.A.

6. The share of voting rights held by Allianz Global Investors GmbH, Munich, Germany, in STRATEC Biomedical AG, Gewerbestr. 37, 75217 Birkenfeld, Germany, exceeded the threshold of 5% on December 10, 2013 and amounted to 5.11% of all voting rights in the company, corresponding to 601,001 of the total 11,770,245 voting rights. These voting rights are attributed pursuant to section 22 (1) sentence 1 number 6 in conjunction with sentence 2 of the German Securities Trading Act (WpHG).
Of these, 600,000 voting rights were also attributable to us pursuant to section 22 (1) sentence 1 number 6 in conjunction with sentence 2 of the German Securities Trading Act (WpHG) via a shareholder whose share of voting rights amounted to 3% or more: Allianz I.A.R.D. S.A.

7. The share of voting rights held by Allianz Global Investors France S.A., Paris, France, in STRATEC Biomedical AG, Gewerbestr. 37, 75217 Birkenfeld, Germany, exceeded the threshold of 5% on December 10, 2013 and amounted to 5.15% of all voting rights in the company, corresponding to 606,045 of the total 11,770,245 voting rights. These voting rights are attributed pursuant to section 22 (1) sentence 1 number 6 of the German Securities Trading Act (WpHG).

Of these, 600,000 voting rights were also attributable to us pursuant to section 22 (1) sentence 1 number 6 of the German Securities Trading Act (WpHG) via a shareholder whose share of voting rights amounted to 3% or more: Allianz I.A.R.D. S.A.'



16.12.2013 DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---

 
Language:     English
Company:      STRATEC Biomedical AG
              Gewerbestr. 37
              75217 Birkenfeld
              Germany
Internet:     www.stratec.com
 
End of Announcement DGAP News-Service  

---